{"id":"W4399722033","doi":"10.1016/j.ejca.2024.114183","title":"Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Janssen Pharmaceuticals; AstraZeneca; Pfizer; Amgen; Astellas Pharma; Abbott Laboratories","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Oncology; Covariate; Internal medicine; Placebo; Cancer; Statistics; Androgen deprivation therapy; Mathematics; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01120503,0.000760912,0.002520556,0.0003535117,0.0003792755,0.001249333,0.0006446483,0.0004605115,0.002313241],"category_scores_gemma":[0.01200983,0.0003499273,0.003179913,0.000781861,0.0003775801,0.0008917736,0.0005421865,0.001578787,0.0003503853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003931535,"about_ca_system_score_gemma":0.0008095626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005961736,"about_ca_topic_score_gemma":0.001297873,"domain_scores_codex":[0.990928,0.006695796,0.0004824342,0.0008625483,0.0007286811,0.0003024836],"domain_scores_gemma":[0.9933354,0.002967151,0.001668045,0.001428156,0.0002784908,0.0003228132],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5157173,0.001253697,0.286419,0.0007271966,0.02955798,0.0003465033,0.0001733793,0.002935491,0.01423134,0.0005106521,0.005883497,0.142244],"study_design_scores_gemma":[0.05017446,0.03552423,0.8643519,0.0001629061,0.0236296,0.0009070228,0.0001260066,0.005030908,0.003879621,0.002852966,0.0132648,0.00009547522],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98026,0.009054977,0.003706148,0.001086677,0.0006166002,0.0003053368,0.001989956,0.0001430687,0.002837149],"genre_scores_gemma":[0.9950501,0.0005564544,0.001789971,0.0004154797,0.0002450038,0.0001099281,0.001291974,0.00004388539,0.0004972338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01120503,"threshold_uncertainty_score":0.05925858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04673604915791438,"score_gpt":0.3859914848494938,"score_spread":0.3392554356915795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}